ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

New indication for ZYTIGA® in combination with prednisone provides treatment option for patients with metastatic high-risk castration-sensitive prostate cancer Findings from pivotal Phase 3 LATITUDE clinical trial data demonstrated statistically sig... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, ZYTIGA, abiraterone, prostate cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news